Rewriting the Rules of Informed Consent
A look at efforts to include individuals with intellectual and developmental disabilities in clinical research
When hematologist/oncologist Cecilia Arana Yi, MD, first saw George (name changed to protect identity) in her clinic at the University...
Online Exclusives
FDA Places Clinical Hold on Studies of Allogeneic CAR T-Cell Therapy
The U.S. Food and Drug Administration (FDA) has placed a clinical hold on two phase I trials of gene-edited allogeneic chimeric antigen receptor (CAR)...
Hurricane Harvey Flooding Causes High Levels of Carcinogenic Substance
Flooding from Hurricane Harvey damaged an oil refinery in Houston, Texas, releasing dangerous amounts of the carcinogen benzene into the air. The compound is...
News
From the Blood Journals
Fertility Issues in Patients With Inherited Bone Marrow Failure Syndromes
More patients with inherited bone marrow failure syndromes (IBMFS) are surviving to adulthood. As they do, they face barriers to pregnancy. It is still...
Number of Older Patients Receiving AlloHCT Increased Over the Past Decade
Historically, older adults have not been considered optimal candidates for hematopoietic cell transplantation (HCT) because of concerns about transplant-related toxicity and mortality. Over the...
Latest Videos
pASHions: B.Y.O.B. (Build Your Own Boat) With Joseph H. Antin, MD
In more from our interview with Dr. Antin, he offers two simple rules for starting a new hobby with your spouse, and discusses the...
Pulling Back the Curtain: Gerald A. Soff, MD
Hear more from our interview with Dr. Soff, where he shares more about his career in hematology, his myeloma diagnosis, and why Sergio Giralt, MD, is...
Eytan M. Stein, MD: Enasidenib Shows “Encouraging” Efficacy in IDH2-Mutated AML
Treatment with the IDH2 inhibitor enasidenib was well-tolerated and led to an "impressive" response rate in patients with relapsed/refractory IDH2-mutated acute myeloid leukemia. Dr....
Jae Hong Park, MD: Improving Outcomes, Minimizing Toxicity With CAR T-Cell...
Dr. Park reviews two studies identifying characteristics that can improve durability of outcome, without increasing toxicity, in patients with B-cell acute lymphocytic leukemia.
On Location
Emicizumab Significantly Decreases Bleeding Rate, Compared With No Treatment in Patients With Hemophilia A
In the phase III HAVEN-1 study, preventive treatment with emicizumab significantly reduced bleeding rates, compared...
RNA Interference Therapy Fitusiran Improves Thrombin Generation in Patients With Hemophilia
The investigational RNA interference therapy fitusiran lowered levels of antithrombin in patients with hemophilia A...
Is Anticoagulant Therapy to Prevent Recurrent VTE Worth the Bleeding Risk in Older Patients With Cancer?
Though anticoagulants are common frontline treatment for patients with venous thromboembolism (VTE), patients with cancer...
Phase II Results Show Activity of Polatuzumab Vedotin Combination in DLBCL
The CD79b-targeting antibody drug conjugate polatuzumab vedotin, in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone...
Evaluating HCT Outcomes in Patients With Beta-Thalassemia
Hematopoietic cell transplantation (HCT) is associated with a disease-free survival rate of 90 percent at...
Fourth Drug’s the Charm? Comparing Combination Therapies in the Myeloma XI Trial
Triplet combinations of anti-myeloma induction therapies lead to deeper, longer remissions than doublet combinations. Results...
Latest Headlines
ASH Directions
2017 ASH Clinical Research Training Institute Participants, AML Matters Summit, and more
Fellows and Junior Faculty Selected for 2017 ASH Clinical Research Training Institute
Twenty hematology and hematology/oncology fellows and junior faculty will participate in the 2017...
ASH Selects Outstanding Trainees for Award Programs, Honorific Award Winners, and more
ASH Selects Outstanding Trainees for Award Programs
2017 ASH Research Training Award for Fellows
ASH selected 11 fellows for the 2017 ASH Research Training Award for...
New CDC Director Named, NIH Awards Grants for Cancer Cell Metastases, and more
Brenda Fitzgerald Named New Director of the Centers for Disease Control and Prevention
Brenda Fitzgerald, MD, the Georgia Public Health Commissioner, has been appointed director...
Ned Sharpless Named New NCI Director, 2017 Pew-Stewart Cancer Research Scholars Announced, and more
Norman Sharpless Named Director of the National Cancer Institute
Norman “Ned” Sharpless, MD, has been appointed director of the National Cancer Institute (NCI) by President...
Remembering H. Jean Khoury, NCI Funds Standardization of Cancer Genomic Data, and more
Remembering H. Jean Khoury (1967-2017)
H. Jean Khoury, MD, an expert in hematologic malignancies at the Winship Cancer Institute of Emory University, died at age...
Rewriting the Rules of Informed Consent
A look at efforts to include individuals with intellectual and developmental disabilities in clinical research
When hematologist/oncologist Cecilia Arana Yi, MD, first saw George (name...
The Geography of Drug Approvals
How can regulators look at the same data and get different results?
The goal of regulatory bodies such as the U.S. Food and Drug Administration...
It Runs in the Blood
For these doctors, hematology is “the family business”
The term “family business” may conjure images of stores, restaurants, and other commercial enterprises, but it turns...
